Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye

Gou Young Koh; Hellmut G. Augustin; Peter A. Campochiaro

doi:10.1016/j.molmed.2022.03.004

Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye

Gou Young Koh
, Hellmut G. Augustin
, Peter A. Campochiaro

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

Abstract

Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.

Original language	English (US)
Pages (from-to)	347-349
Number of pages	3
Journal	Trends in Molecular Medicine
Volume	28
Issue number	5
DOIs	https://doi.org/10.1016/j.molmed.2022.03.004
State	Published - May 2022

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology

Access to Document

10.1016/j.molmed.2022.03.004

Cite this

@article{5f29bf40c5b74d9f95b5f2a7bf11f1e9,

title = "Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye",

abstract = "Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.",

author = "Koh, \{Gou Young\} and Augustin, \{Hellmut G.\} and Campochiaro, \{Peter A.\}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = may,

doi = "10.1016/j.molmed.2022.03.004",

language = "English (US)",

volume = "28",

pages = "347--349",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Viewpoints

T2 - Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye

AU - Koh, Gou Young

AU - Augustin, Hellmut G.

AU - Campochiaro, Peter A.

PY - 2022/5

Y1 - 2022/5

N2 - Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.

AB - Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.

UR - https://www.scopus.com/pages/publications/85127502196

UR - https://www.scopus.com/pages/publications/85127502196#tab=citedBy

U2 - 10.1016/j.molmed.2022.03.004

DO - 10.1016/j.molmed.2022.03.004

M3 - Short survey

C2 - 35396185

AN - SCOPUS:85127502196

SN - 1471-4914

VL - 28

SP - 347

EP - 349

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 5

ER -

Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this